The following article features coverage from the National Kidney Foundation’s 2019 Spring Clinical Meetings. Click here to read more of Renal & Urology News’ conference coverage.
Elevated levels of c-terminal fibroblast growth factor 23 (cFGF23) in patients who have heart failure with preserved ejection fraction (HFpEF) are associated with worse clinical parameters, according to study findings presented at the National Kidney Foundation’s 2019 Spring Clinical Meetings in Boston.
The study included 172 patients with HFpEF. At baseline, 86 patients had cFGF23 levels above the median (208.7 RU/mL) and 86 had levels below the median. The main outcome measures were 6-minute walk distance and peak oxygen uptake on cardiopulmonary exercise testing.
Compared with patients who had cFGF23 levels below the median, those with levels above the median had a significantly shorter 6-minute walk distance (mean 288.9 vs 341.8 m) and lower peak oxygen uptake (mean 11.3 vs 13.4 mL/kg/min), Jasleen K. Ghuman, MD, of Northwestern University Feinberg School of Medicine in Chicago, and colleagues reported in a poster presentation. They also had a significantly lower estimated glomerular filtration rate (mean 58.3 vs 69.6 mL/min/1.73 m2), lower systolic blood pressure (mean 121.9 vs 132.4 mm Hg), and higher pro-BNP values (mean 880 vs 572 pg/mL).
After adjusting for age, sex, diabetes, systolic blood pressure, C-reactive protein and eGFR, cFGF23 was significantly associated with worse 6-minute walk distance and peak oxygen consumption, according to the investigators.
Read more of Renal & Urology News’ coverage of NKF’s 2019 Spring Clinical Meetings by visiting the conference page.
Ghuman JK, Cai X, Heckman J, et al. Fibroblast growth factor 23 in heart failure with preserved ejection fraction. Poster presented at the National Kidney Foundation’s 2019 Spring Clinical Meetings in Boston, May 8-12. Poster 196.
This article originally appeared on Renal and Urology News